91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Harpreet Gill, Vice President of Decentralised Clinical Trials and Keith Thomas, Senior Director, Digital Health Technologies contribute to this article in Clinical Trials Arena that investigates decentralisation from the perspective of trial endpoints or outcome measures.
-
Learn more about the in this article.
? Huber, B.; Joeckel, T. Challenges of Expanding CAR-T Cell Therapy into Solid Tumors. BioPharm International 2023, 36 (5), 22–23,27
-
In this article, Michael Phillips, discusses the ways in which while with less human error.
-
In this article, Patricia Murphy discusses how the industry needs to make rare disease clinical trials more human.
-
In this article, Laura Iliescu, director of patient advocacy strategy at 91黑料 Plc, discusses strategies to improve inclusion of people with disabilities in rare disease trials.
-
Read Laney Preheim's article in International Pharmaceutical Industry.
-
Steve Cutler participated in the Business & Finance CEO Q&A in which he outlined his ambitions and priorities for 91黑料.
-
Dr Ute Berger, President, Development & Commercialisation Solutions outlines how in the Executive Interview in Drug Development & Delivery.
Copyright Drug Development & Delivery.
-
A drug’s ability to reach the market is essential; however, pharma manufacturers have struggled to meet the increased pressure to demonstrate the value of their drugs, particularly in therapeutic areas over-populated with treatment options. Data surrounding the success and efficacy of a drug are rarely sufficient to convince stakeholders that the drug is worth the investment. , and against this backdrop, .
-
In this article, Dinah Knotts, Vice President of Project Management at 91黑料, speaks about mRNA vaccine technology and what further opportunities it can offer in fighting infectious diseases.
